ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex: BTX) today announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the ...
ALAMEDA, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which ...
ESI-014 and ESI-017 approved for use in Federally funded research ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the ...
On November 10, BioTime is presenting latest earnings. Analysts expect BioTime will report losses per share of $0.035. Track BioTime stock price in real-time on Markets Insider here. BioTime reveals ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback